Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Saba Capital Management, L.P., a ten percent owner of abrdn Life Sciences Investors (NYSE:HQL), sold 15,116 shares of common stock on September 11, 2025. The shares were sold at a price of $14.28, for a total transaction value of $215,856. The $403 million market cap company has delivered impressive returns this year, with a YTD total return of 19.2%. According to InvestingPro, HQL maintains a notable dividend yield of ~12% and has sustained dividend payments for 30 consecutive years.
Following the transaction, Saba Capital Management, L.P. directly owns 2,953,507 shares of abrdn Life Sciences Investors. The fund currently maintains a FAIR financial health score of 2.5 out of 5, according to InvestingPro, which offers 3 additional key insights about the company’s financial position and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.